Journal of Pharmaceutics / 2018 / Article / Tab 3 / Research Article
The Challenges and Knowledge Gaps in Malaria Therapy: A Stakeholder Approach to Improving Oral Quinine Use in the Treatment of Childhood Malaria in Ghana Table 3 Knowledge on the availability of some antimalarial drugs.
Antimalarial drug Strongly agree ( ) Agree ( ) Neutral ( ) Disagree ( ) Strongly disagree ( ) Chloroquine 57.5 32.8 5.5 1.5 2.8 Quinine 66 25.8 5.2 1.3 1.6 Amodiaquine 59.6 30.5 6.3 1.7 1.9 Halofantrine 17 16.7 41.6 13.8 11 Primaquine 12.7 16.3 44.1 14.6 12.3 Mefloquine 11.6 17.6 43.9 2.7 12.4 Artesunate 57.1 22.5 12.6 3.1 4.8 Dihydroartemisinin 18.9 23.8 34.4 13.2 9.8 Piperaquine 12.4 24.6 36.8 14.3 11.9 Sulfadoxine & Pyrimethamine 19.5 20.9 34.6 12.7 12.3 ACTs Artesunate + amodiaquine 69.5 22.5 4.3 1.3 2.4 Artemether + lumefantrine 61 25.5 8.2 2.4 2.9 Dihydroartemisinin + piperaquine 21.1 25.3 33.2 11.9 8.6 Artesunate + Mefloquine 10.8 21.4 40.1 16.8 10.8 Artesunate + Sulfadoxine & Pyrimethamine 12.2 22.2 39.3 15.6 10.8 Marketed Brands of ACTs Lonart 63.8 28.5 4.5 1.1 2.1 Coartem 57.8 29.4 7 2.5 3.3 Lumether 50.9 27.5 14.3 3.3 3.9 Malar- 43.3 23.7 19.7 7 6.4 P-Alaxin 35.3 24.9 24.5 8 7.4 Danmether 31 20.5 31 9 8.6 Gen-M 34.5 15.6 25.4 9.8 14.7